ADC Therapeutics (ADCT) director receives 45,000 RSUs and 2,156-share tax withholding

Rhea-AI Filing Summary

ADC Therapeutics SA director Peter Hug reported routine equity compensation activity. On June 1, 2026, he received a grant of 45,000 Common Shares in the form of restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for service as a director.

The RSUs vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, subject to his continued service. On June 3, 2026, 2,156 Common Shares were withheld by the company to satisfy his tax withholding obligations upon vesting of previously granted RSUs, a non-market, tax-related disposition rather than an open-market sale.

Following these transactions, Hug directly holds 263,344 Common Shares of ADC Therapeutics SA.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hug Peter

Role null

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares	2,156	$3.08	$7K
Grant/Award	Common Shares	45,000	$0.00	--

Holdings After Transaction: Common Shares — 263,344 shares (Direct, null)

Footnotes (1)

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Key Figures

RSU grant size: 45,000 shares Tax withholding shares: 2,156 shares Tax withholding price: $3.08 per share +2 more

5 metrics

RSU grant size 45,000 shares Annual director RSU grant on June 1, 2026

Tax withholding shares 2,156 shares Shares withheld to cover tax obligations on June 3, 2026

Tax withholding price $3.08 per share Implied price for 2,156 withheld shares

Holdings after transactions 263,344 shares Direct Common Share holdings following reported transactions

Holdings after grant 265,500 shares Direct holdings immediately after 45,000-share RSU grant

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, tax withholding obligations, grant, award, or other acquisition, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"made under the Issuer's 2019 Equity Incentive Plan for service as a Director"

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

Payment of exercise price or tax liability by delivering securities financial

"transaction_code_description": "Payment of exercise price or tax liability by delivering securities"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hug Peter

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		45,000(1)	A	$0	265,500	D
Common Shares	06/03/2026		F(2)		2,156	D	$3.08	263,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-Fact for Peter Hug	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ADC Therapeutics (ADCT) director Peter Hug report?

Peter Hug reported an equity grant and a tax-related share withholding. He received 45,000 restricted stock unit-based Common Shares and had 2,156 shares withheld to cover tax obligations from vesting of prior RSUs.

How many ADC Therapeutics (ADCT) shares does Peter Hug hold after these transactions?

After the reported transactions, Peter Hug directly holds 263,344 Common Shares of ADC Therapeutics SA. This figure reflects both the 45,000-share RSU grant and the 2,156-share tax withholding related to previously vested restricted stock units.

What was the nature of the 45,000-share award to ADC Therapeutics (ADCT) director Peter Hug?

The 45,000-share award was an annual grant of restricted stock units under ADC Therapeutics’ 2019 Equity Incentive Plan. It compensates Hug for service as a director and vests based on time and the 2027 Annual Meeting of Shareholders conditions.

Why were 2,156 ADC Therapeutics (ADCT) shares disposed of in Peter Hug’s Form 4?

The 2,156 shares were withheld by ADC Therapeutics to satisfy Peter Hug’s tax withholding obligations from vesting restricted share units. This “F” code disposition reflects a tax payment mechanism, not an open-market sale or discretionary reduction of his investment.

When do Peter Hug’s newly granted ADC Therapeutics (ADCT) RSUs vest?

The RSUs granted to Peter Hug vest on the earlier of one year from the June 1, 2026 grant date or the date of ADC Therapeutics’ 2027 Annual Meeting of Shareholders, assuming he continues providing service as a director throughout that period.